Entrada Therapeutics, Inc.

NasdaqGM:TRDA Stock Report

Market Cap: US$621.7m

Entrada Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:TRDA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
11 Dec 24SellUS$917,111MPM BioImpact LLCCompany44,722US$20.77
14 May 24BuyUS$364,673Peter KimIndividual25,000US$14.59
09 May 24BuyUS$63,306Peter KimIndividual4,476US$14.25
08 Apr 24BuyUS$35,290Peter KimIndividual2,600US$13.57
28 Mar 24BuyUS$20,794Peter KimIndividual1,512US$13.75
26 Mar 24BuyUS$122,882Peter KimIndividual9,048US$13.76
21 Mar 24BuyUS$34,996Peter KimIndividual2,732US$13.24

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of TRDA?
Owner TypeNumber of SharesOwnership Percentage
General Public198,7200.561%
Individual Insiders498,1251.41%
Public Companies2,744,1207.75%
Hedge Funds4,865,81913.7%
VC/PE Firms8,789,44124.8%
Institutions18,309,14251.7%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.2%.

Top Shareholders

Top 25 shareholders own 92.03% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
13.7%
Baker Bros. Advisors LP
4,865,819US$85.4m0%0.86%
12.5%
5AM Venture Management, LLC
4,408,379US$77.4m0%17.1%
12.4%
MPM BioImpact LLC
4,381,062US$76.9m-1.01%60.73%
8.61%
T. Rowe Price Group, Inc.
3,049,572US$53.6m-2.71%no data
7.75%
Roche Holding AG
2,744,120US$48.2m0%no data
5.15%
BlackRock, Inc.
1,822,835US$32.0m7.61%no data
4.92%
FMR LLC
1,743,448US$30.6m-4.69%no data
4.91%
M Ventures
1,739,768US$30.6m0%94.16%
4.83%
Janus Henderson Group plc
1,711,459US$30.1m10.5%0.01%
3.45%
The Vanguard Group, Inc.
1,223,185US$21.5m8.28%no data
2.91%
Wellington Management Group LLP
1,029,369US$18.1m-0.44%no data
2.15%
StepStone Group Inc.
761,277US$13.4m0%3.85%
1.65%
TCG Crossover Management, LLC
584,955US$10.3m0%0.94%
1.63%
Geode Capital Management, LLC
576,451US$10.1m8.78%no data
1.33%
State Street Global Advisors, Inc.
469,601US$8.2m5.48%no data
0.7%
Northern Trust Global Investments
247,680US$4.3m30.2%no data
0.57%
Jacobs Levy Equity Management Inc
201,803US$3.5m50.3%0.01%
0.53%
Charles Schwab Investment Management, Inc.
185,984US$3.3m14.6%no data
0.39%
Connor, Clark & Lunn Investment Management Ltd.
138,605US$2.4m132%0.01%
0.36%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
128,336US$2.3m5.77%no data
0.35%
Nathan Dowden
125,149US$2.2m1,230%no data
0.35%
Dipal Doshi
123,891US$2.2m4.71%no data
0.31%
Millennium Management LLC
110,943US$1.9m-24.7%no data
0.3%
Moore Capital Management, LP
105,000US$1.8m0%0.06%
0.3%
BNY Asset Management
104,967US$1.8m-16.3%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 12:39
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Entrada Therapeutics, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chris ShibutaniGoldman Sachs
Raghuram SelvarajuH.C. Wainwright & Co.
Boobalan PachaiyappanH.C. Wainwright & Co.